References
- Viruses Coronaviridae Study Group of the International Committee on Taxonomy of. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544.
- Naming the coronavirus disease (COVID-19) and the virus that causes it; 2020 [cited 2020 Oct 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
- Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–734.
- Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;39(9):1629–1635.
- Zhu Z, Lian X, Su X, et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21(1):224.
- Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020;30(17):127377.
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
- Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
- Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–e44.
- Mori M, Capasso C, Carta F, et al. A deadly spillover: SARS-CoV-2 outbreak. Expert Opin Ther Pat. 2020;30(7):481–485.
- Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update; 2020 [cited 2020 Oct 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- COVID-19 integrated surveillance data in Italy; 2020 [cited 2020 Oct 31]. Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-dashboard
- AIFA - COVID-19 Emergency; 2020. [cited 2020 Oct 31]. Available from: https://www.aifa.gov.it/en/emergenza-covid-19
- EMA - Coronavirus disease (COVID-19); 2020. [cited 2020 Oct 31]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19
- FDA - Coronavirus disease 2019 (COVID-19); 2020 [cited 2020 Oct 31]. Available from: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19
- Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38(4):379–381.
- Arisi I, Mantuano E. Age and gender distribution of COVID-19 infected cases in Italian population. Research Square 2020.
- COVID-19 cases by age group and sex; 2020 [cited 2020 Oct 31]. Available from: https://www.health.gov.au/resources/covid-19-cases-by-age-group-and-sex
- Pastor-Barriuso R, Perez-Gomez B, Hernan MA, et al. Infection fatality risk for SARS-CoV-2: a nationwide seroepidemiological study in the non-institutionalized population of Spain. BMJ 2020;371:m4509. https://doi.org/10.1136/bmj.m4509
- Demographic data for coronavirus (COVID-19) testing (England): 28 May to 26 August; 2020 [cited 2020 Oct 31]. Available from: https://www.gov.uk/government/publications/demographic-data-for-coronavirus-testing-england-28-may-to-26-august/demographic-data-for-coronavirus-covid-19-testing-england-28-may-to-26-august
- Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.
- Nasiri MJ, Haddadi S, Tahvildari A, et al. COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis. Front Med (Lausanne). 2020;7:459.
- Azuma K, Yanagi U, Kagi N, et al. Environmental factors involved in SARS-CoV-2 transmission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control. Environ Health Prev Med. 2020;25(1):66.
- Eslami H, Jalili M. The role of environmental factors to transmission of SARS-CoV-2 (COVID-19). AMB Express. 2020;10(1):92.
- Roviello V, Roviello GN. Lower COVID-19 mortality in Italian forested areas suggests immunoprotection by mediterranean plants. Environ Chem Lett. 2020:1–12.
- COVID-19: MAGIC making a difference and MAGICapp now available to develop living guidelines; 2020 [cited 2020 Oct 31]. Available from: https://magicevidence.org/
- Bellali H, Chtioui N, Chahed M. Factors associated with country-variation in COVID-19 morbidity and mortality worldwide: an observational geographic study. medRxiv. 2020. 2020.05.27.20114280
- North CM, Dougan ML, Sacks CA. Improving clinical trial enrollment - In the Covid-19 era and beyond. N Engl J Med. 2020;383(15):1406–1408.
- Chow SC, Zhang W. Statistical evaluation of clinical trials under COVID-19 pandemic. Ther Innov Regul Sci. 2020;54:1551–1556.
- Mullard A. Parsing clinical success rates. Nat Rev Drug Discov. 2016;15(7):447.
- Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495–496.
- Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
- Pillaiyar T, Meenakshisundaram S, Manickam M, et al. A medicinal chemistry perspective of drug repositioning: recent advances and challenges in drug discovery. Eur J Med Chem. 2020;195:112275.
- Guy RK, DiPaola RS, Romanelli F, et al. Rapid repurposing of drugs for COVID-19. Science. 2020;368(6493):829–830.
- Wang JM. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020;60(6):3277–3286.
- Wang XQ, Guan YF. COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev. 2020. DOI:10.1002/med.21728
- Zhou Y, Wang F, Tang J, et al. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020;2(12):e667–e676.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Riva L, Yuan SF, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113–119.
- Singh TU, Parida S, Lingaraju MC, et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479–1508.
- Baby K, Maity S, Mehta CH, et al. Targeting SARS-CoV-2 main protease: a computational drug repurposing study. Arch Med Res. 2020. S0188-4409(20)30957-7..
- Jin Z, Du X, Xu Y, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
- Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11(1):5047.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
- Sisay M. 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: available evidence and ongoing clinical trials. Pharmacol Res. 2020;156:104779.
- Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352.
- Ahmad J, Ikram S, Ahmad F, et al. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study. Heliyon. 2020;6(7):e04502.
- Pan H, Peto R, Abdool Karim Q, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. New England Journal of Medicine doi: 10.1056/NEJMoa2023184.
- Dragoni F, Boccuto A, Picarazzi F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res. 2020;175:104708.
- FDA approves first treatment for COVID-19; [ cited 31 Oct 2020]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
- Veklury; 2020 [cited 2020 Oct 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/veklury#authorisation-details-section
- Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–468.
- Hillen HS, Kokic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584(7819):154–156.
- Zhu W, Chen CEZ, Gorshkov K, et al. RNA-dependent RNA polymerase as a target for COVID-19 drug discovery. Slas Discov. 2020;25(10):1141–1151.
- ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world; 2020 [cited 2020 Oct 31]. Available from: https://www.clinicaltrials.gov/
- Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396).
- Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. Mbio. 2018;9(2):e00221–18.
- Pardo J, Shukla AM, Chamarthi G, et al. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:2020.
- Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499–1504.
- “Solidarity” clinical trial for COVID-19 treatments; [ cited 31 Oct 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
- Burki TK. Completion of clinical trials in light of COVID-19. Lancet Respir Med. 2020;8(12):1178–1180.
- Humeniuk R, Mathias A, Cao HY, et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci. 2020;13(5):896–906.
- Elsawah HK, Elsokary MA, Abdallah MS, et al. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2020;e2187.
- Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;14(5):881–883.
- Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol. 2020;18(12):2835–2836.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
- Conditional marketing authorisation; [ cited 31 Oct 2020]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation
- Coronavirus: commission signs a joint procurement contract with Gilead for the supply of Remdesivir; 2020 [cited 2020 Oct 31]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/ip_20_1845
- Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454.
- Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. 2020.03.17.20037432.
- Huang X, Xu Y, Yang Q, et al. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials. Sci Rep. 2015;5:8528.
- Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial (vol 15, pg 785, 2015). Lancet Infect Dis. 2015;15(8):875.
- Lopinavir/ritonavir in the therapy of adults patients with COVID-19; [ cited 31 Oct 2020]. Available from: https://www.aifa.gov.it/documents/20142/1123276/lopinavir_ritonavir_17.07.2020.pdf/ab9e07d8-585b-6eda-0007-a8f3d1e175c4
- Slomski A. No benefit for lopinavir-ritonavir in severe COVID-19. Jama-J Am Med Assoc. 2020;323(20):1999.
- Giacomelli A, Pagani G, Ridolfo AL, et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2020;in press. DOI:10.1002/jmv.26407
- Meini S, Pagotto A, Longo B, et al. Role of lopinavir/ritonavir in the treatment of Covid-19: a review of current evidence, guideline recommendations, and perspectives. J Clin Med. 2020;9(7):2050.
- Solomon VR, Lee H. Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625(1–3):220–233.
- Yan YW, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–302.
- Liu J, Cao RY, Xu MY, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1)1–4.
- Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727.
- Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960.
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
- Song W, Muste JC, Greenlee TE, et al. Chloroquine and hydroxychloroquine toxicity. Am J Ophthalmic Clin Trials. 2020;3(8):1–6.
- Yogasundaram H, Hung W, Paterson ID, et al. Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. Esc Heart Fail. 2018;5(3):372–375.
- Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77–83.
- Della Porta A, Bornstein K, Coye A, et al. Acute chloroquine and hydroxychloroquine toxicity: a review for emergency clinicians. Am J Emerg Med. 2020;38(10):2209–2217.
- WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19; [ cited 31 Oct 2020]. Available from: https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
- COVID-19: reminder of the risks of chloroquine and hydroxychloroquine; 2020 [cited 2020 Oct 31]. Available from: https://www.ema.europa.eu/en/documents/press-release/covid-19-reminder-risks-chloroquine-hydroxychloroquine_en.pdf
- AIFA - clinical trials COVID-19; 2020 [cited 2020 Oct 31]. Available from: https://www.aifa.gov.it/en/web/guest/sperimentazioni-cliniche-covid-19
- FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems; 2020 [cited 2020 Oct 31]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
- Recovery Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020:NEJMoa2021436. DOI:10.1056/NEJMoa2021436.
- Corticosteroids for COVID-19; 2020 [cited 2020 Oct 31]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1
- Corticosteroids in the therapi of adult patients with COVID-19; [ cited 31 Oct 2020]. Available from: https://www.aifa.gov.it/documents/20142/1123276/Corticosteroidi_06.10.2020.pdf/075c9302-895c-4d7e-11bc-0e2319082ffc
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation; 2020 [cited 2020 Oct 31]. Available from: https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation
- Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(5):1233–1234.
- Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.
- Low molecular weight heparin in adult patients with COVID-19; 2020 [cited 2020 Oct 31]. Available from: https://www.aifa.gov.it/documents/20142/1123276/Eparine_Basso_Peso_Molecolare_11.04.2020.pdf/e30686fb-3f5e-32c9-7c5c-951cc40872f7
- WHO - Clinical management of COVID-19; [ cited 31 Oct 2020]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19
- Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ, et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Therapeut. 2014;143(2):225–245.
- Zimmermann P, Ziesenitz VC, Curtis N, et al. The Immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.
- Arabi YM, Deeb AM, Al-Hameed F, et al. Macrolides in critically ill patients with Middle East respiratory syndrome. Int J Infect Dis. 2019;81:184–190.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
- Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384.
- Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–809.
- Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425–1433.
- Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967.
- Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041–2052.
- Zhang X, Zhang Y, Qiao W, et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020;86:106749.
- Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):E30–E31.
- Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients. EMBO Mol Med. 2020;12:e12697.
- Stebbing J, Nievas GS, Falcone M, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2020;eabe4724.
- Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19; 2020 [cited 2020 Nov 30]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
- Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865–1879.
- Galvan-Roman JM, Rodriguez-Garcia SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2020. S0091-6749(20)31329-4.
- Tocilizumab in COVID-19 pneumonia (TOCIVID-19); 2020 [cited 2020 Oct 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04317092
- Chiodini P, Arenare L, Piccirillo MC, et al. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): statistical analysis plan. Contemp Clin Trials Commun. 2020;20:100665.
- Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18(1):405.
- Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603–e12.
- Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with covid-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020:e206615.
- Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698.
- Gremese E, Cingolani A, Bosello SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020;27:100553.
- Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–1285.
- Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS); 2020 [cited 2020 Nov 30]. Available from: https://www.novartis.com/news/media-releases/novartis-provides-update-can-covid-trial-hospitalized-patients-covid-19-pneumonia-and-cytokine-release-syndrome-crs
- Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400.
- De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2(8):E465–E73.
- Khan NA. Anakinra for severe forms of COVID-19. Lancet Rheumatol. 2020;2(10):e586–e87.
- Mullard A. Anti-IL-6Rs falter in COVID-19. Nat Rev Drug Discov. 2020;19(9):577.
- Bilia S, Giannini D, Rizzelli GML, et al. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still’s disease? Clin Exp Rheumatol. 2020;38(3):579.
- Nascimento Junior JAC, Santos AM, Quintans-Junior LJ, et al. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review. Expert Opin Ther Pat. 2020;30(8):567–579.
- Bonadio E, Baldini A. COVID-19, patents and the never-ending tension between proprietary rights and the protection of public health. Eur J Risk Regul. 2020;11(2):390–395.
- O’ Neil M, Clarke H, Feng JY, et al. Inc. Gilead Sciences, Methods for treating arenaviridae and coronaviridae virus infections patent WO2017049060A1. 2017.
- Nandi I, Jain A. Jubilant generics limited, transmucosal dosage forms of remdesivir Patent application number: 202011022634. 2020.
- Ivashchenko AA, Ivashchenko AV, Savchuk NF, et al. Anti-Covid-19 (SARS-COV-2) viral pharmaceutical composition Patent application number: 2020116521. 2020.
- Addington OC, Newman RA. Inc Phoenix Biotechnology, Method and compostitions for treating coronavirus infection USA patent 10729735. 2020.
- Brambilla R, Bramlett HM, Dietrich WD, et al. University of miami, methods and compositions for treating virus-associated inflammation USA patent Patent 16/856407. 2020.
- Peyman GA. Method of treating, reducing, or alleviating a medical condition in a patient patent 16/861128. 2020.